New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

(2010) F. Morschhauser et al.   ANNALS OF ONCOLOGY

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

(2010) C. Henry et al.   BLOOD

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Current and Emerging Treatments for Chronic Lymphocytic Leukaemia

(2010) Tadeusz Robak et al.   DRUGS

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

(2010) David M. Goldenberg et al.   LEUKEMIA & LYMPHOMA

CD20-Targeted Therapy: The Next Generation of Antibodies

(2010) Tom van Meerten et al.   SEMINARS IN HEMATOLOGY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies

(2010) Stephen A. Beers et al.   SEMINARS IN HEMATOLOGY

CD20-Directed Small Modular Immunopharmaceutical, TRU-015, Depletes Normal and Malignant B Cells

(2009) M. S. Hayden-Ledbetter et al.   CLINICAL CANCER RESEARCH

Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity

(2009) Tadeusz Robak   CURRENT MEDICINAL CHEMISTRY

Ocrelizumab: a step forward in the evolution of B-cell therapy

(2009) Fariha Kausar et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia

(2009) James Weitzman et al.   LEUKEMIA & LYMPHOMA

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

(2009) Claudia Stolz et al.   LEUKEMIA & LYMPHOMA

Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20

(2009) Jiamu Du et al.   MOLECULAR IMMUNOLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Novel human antibody therapeutics: The age of the Umabs

(2008) Sigrid R. Ruuls et al.   Biotechnology Journal

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

(2008) A. Hagenbeek et al.   BLOOD

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A phase I, open-label, dose-escalation clinical study

(2008) Daniel J. Burge et al.   CLINICAL THERAPEUTICS

Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

(2008) Tadeusz Robak   CURRENT CANCER DRUG TARGETS

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

(2008) Ronald P Taylor et al.   CURRENT OPINION IN IMMUNOLOGY

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

(2008) X. Zhou et al.   ONCOLOGIST

Novel and Engineered Anti–B-Cell Monoclonal Antibodies for Non-Hodgkin’s Lymphoma

(2008) Peter Martin et al.   SEMINARS IN HEMATOLOGY